February 21, 2017
‘Fasting-mimicking’ diet said to reduce risk factors for aging
Following a diet that mimics fasting may reduce risk factors for disease in generally healthy people, according to a small study.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Middle East and North Africa
February 13, 2017
Hikma won exclusive licensing and distribution agreement for pulmonary disease drug
Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland (Orion), for its new Easyhaler combination product, a dry powder inhaler (DPI) of budesonide and formoterol, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
February 9, 2017
Pharmaceuticals Analytical Testing Outsourcing Market Worth $9.6 Billion By 2025
The consumption levels are anticipated to rise exponentially over the forecast period. The companies and government organizations are working collaboratively to bridge the gap between supply and demand.
February 9, 2017
Pulmonary drug delivery devices market to reach $43.05 billion by 2024
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
February 2, 2017
MENA biologics industry first ever Biopharma Conference at CPhI Istanbul 2017
With the goal of developing Turkey as an R&D and technology hub, the Government has put place a number of measures to stimulate expansion of biotechnology and biopharmaceutical activities.
January 20, 2017
Where do you stand against influenza
Flu, or influenza, is a very contagious, acute, viral respiratory infection. Influenza viruses vary in a high degree. The extent…
January 5, 2017
Futura Medicals launches condom in Saudi Arabia, expects further distribution in MENA
Transdermal technology specialist Futura Medicalis has made an – at least to say – interesting step in Saudi Arabia, country…
December 1, 2015
Tuberculosis funding gap threatens elimination goals
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
November 17, 2015
Study: Janssen’s OLYSIO safe for treating hepatitis C virus Patients (Egypt)
The OSIRIS trial Phase II a investigating once daily OLYSIO (simeprevir) in combination with sofosbuvir in hepatitis C virus (HCV) genotype 4 infected patients, with and without liver cirrhosis, demonstrated treatment to be safe.
October 12, 2015
Novartis’ Cosentyx provides high level of skin clearance
Novartis has announced new late-breaking data demonstrating that Cosentyx (secukinumab) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years.